Landmark Food and Drug Administration Approvals

09:37 EDT 16 Sep 2013 |

The 2012 fiscial year witnessed  a tremendous milestone for the Food and Drug Administration (FDA) with the approval over 30 new novel drugs to treat rare conditions that range from advance basal cell carcinoma, cystic fibrosis, and orphan diseases. These approval fueled the FDA's mission of providing life-sustaining or life-saving drugs to populations that might otherwise go without proper treatment due to a variety of reasons. Expedited reviews were performed formany of these drugs but quality standards still had to be abide by in order for final approval to be given. Of note, the approval of 10 cancer drugs was idenified as one of the landmark decisions that have produced therapeutic options for individuals with prostate cancer, skin cancer, chronic leukemia, or myelofibrosis to name a few. The future hold great promise additional drugs to be approved that will help to increase the availability of therapeutic treatment options for individuals and helping to improve their conditions.


More From BioPortfolio on "Landmark Food and Drug Administration Approvals"

Quick Search


Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...